Popular weight-loss drugs like GLP-1 receptor agonists may do more than shed pounds — nearly half of users who drank alcohol reported cutting back within 3 months of starting treatment. The effect was even stronger among those with unhealthy drinking habits. But awareness of this potential benefit remains surprisingly low.
GLP-1 receptor agonists (RAs) — the blockbuster class of drugs behind medications like Ozempic and Wegovy — may have an unexpected benefit: reducing alcohol consumption. A nationally representative US survey of over 2,000 adults found that among those who were drinking when they started a GLP-1 RA, 44.2% reported drinking less within just 3 months of starting treatment.
The effect was even more pronounced in people with problematic drinking habits. Among GLP-1 users who screened positive for potentially unhealthy alcohol use, more than half (54.1%) reported cutting back — and they were more than twice as likely to reduce drinking compared to those without unhealthy use patterns (adjusted odds ratio, 2.30).
Despite growing interest in this area, awareness of this potential benefit remains strikingly low. Only 9.7% of participants knew GLP-1 RAs might reduce the urge to drink, compared to 79.3% who knew about their weight-loss effects.
By the Numbers
Why it matters: If confirmed in large clinical trials, GLP-1 RAs could become a dual-purpose tool for clinicians managing patients with both obesity or diabetes and alcohol use concerns — a combination that's far from rare in primary care and psychiatry settings.
